C12N 2810/855
From receptors
Official title: from receptors; from cell surface antigens; from cell surface determinants
C12N2810/855 (From receptors) appears on 81 US grants and 98 published applications in this corpus.
Search patents in C12N- Granted patents
- 81
- Published applications
- 98
- Assignees
- 65
- Inventors
- 185
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 1 |
| 2002 | 5 | 2 |
| 2003 | 0 | 5 |
| 2004 | 0 | 4 |
| 2005 | 4 | 4 |
| 2006 | 4 | 5 |
| 2007 | 0 | 1 |
| 2008 | 1 | 4 |
| 2009 | 1 | 1 |
| 2010 | 2 | 7 |
| 2011 | 1 | 2 |
| 2012 | 4 | 8 |
| 2013 | 3 | 3 |
| 2014 | 6 | 5 |
| 2015 | 5 | 2 |
| 2016 | 3 | 9 |
| 2017 | 2 | 4 |
| 2018 | 2 | 5 |
| 2019 | 8 | 3 |
| 2020 | 4 | 3 |
| 2021 | 2 | 4 |
| 2022 | 2 | 4 |
| 2023 | 2 | 0 |
| 2024 | 2 | 4 |
| 2025 | 5 | 5 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- Oncolytic tumor viruses and methods of use6 Jan 2026US 12,514,887 B2The Salk Institute for Biological Studies
- Use of microvesicles in the treatment of medical conditions16 Dec 2025US 12,497,631 B2The General Hospital Corporation
- Ligand discovery and gene delivery via retroviral surface display28 Oct 2025US 12,455,280 B2Massachusetts Institute of Technology
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Ligand discovery and gene delivery via retroviral surface display29 Jan 2026US 2026/0029398 A1Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display29 Jan 2026US 2026/0029399 A1Massachusetts Institute of Technology
- Retroviral and Lentiviral Vectors25 Dec 2025US 2025/0388929 A1Autolus Limited
- Gene therapy for treating mitochondrial stress4 Dec 2025US 2025/0367329 A1Yissum Research Development Company of the Hebrew University of Jerusalem
Most cited
By later US patents
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996
- Chimeric envelope proteins for viral targeting71US 5,714,316 AThe Trustees of the University of Pennsylvania · 1998
- Adeno-associated virus virions with variant capsid and methods of use thereof59US 9,457,103 B2The Regents of the University of California · 2016
- Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein58US 5,712,136 AGenVec, Inc. · 1998
- Methods and means for targeted gene delivery51US 7,033,834 B2Crucell Holland B. V. · 2006